Cargando…

Characterization of intratumor microbiome in cancer immunotherapy

Detalles Bibliográficos
Autores principales:	Zhang, Zhao, Gao, Qian, Ren, Xiangmei, Luo, Mei, Liu, Yuan, Liu, Peilin, Liu, Yun, Ye, Youqiong, Chen, Xiang, Liu, Hong, Han, Leng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10407538/ https://www.ncbi.nlm.nih.gov/pubmed/37560331 http://dx.doi.org/10.1016/j.xinn.2023.100482

Ejemplares similares

Identification of CircRNA signature associated with tumor immune infiltration to predict therapeutic efficacy of immunotherapy
por: Dong, Yu, et al.
Publicado: (2023)

Sex-associated molecular differences for cancer immunotherapy
por: Ye, Youqiong, et al.
Publicado: (2020)

Immunotherapeutic Agents for Intratumoral Immunotherapy
por: Shyr, Chih-Rong, et al.
Publicado: (2023)

Multi-omics characterization and therapeutic liability of ferroptosis in melanoma
por: He, Yi, et al.
Publicado: (2022)

Intratumoral microbiome and gastrointestinal cancers
por: Li, Shengnan, et al.
Publicado: (2022)

Multi-omics characterization of autophagy-related molecular features for therapeutic targeting of autophagy
por: Luo, Mei, et al.
Publicado: (2022)

Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy
por: Jiang, Xiaoyi, et al.
Publicado: (2022)

Intratumor microbiome features reveal antitumor potentials of intrahepatic cholangiocarcinoma
por: Chai, Xiaoqiang, et al.
Publicado: (2022)

Intratumoral Immunotherapy—Update 2019
por: Hamid, Omid, et al.
Publicado: (2019)

Trial watch: intratumoral immunotherapy
por: Humeau, Juliette, et al.
Publicado: (2021)

The effect of the intratumoral microbiome on tumor occurrence, progression, prognosis and treatment
por: Gao, Feng, et al.
Publicado: (2022)

Intratumor microbiome in cancer progression: current developments, challenges and future trends
por: Liu, Jinyan, et al.
Publicado: (2022)

Current understanding of the intratumoral microbiome in various tumors
por: Xue, Chen, et al.
Publicado: (2023)

Integrated multi-omics identified the novel intratumor microbiome-derived subtypes and signature to predict the outcome, tumor microenvironment heterogeneity, and immunotherapy response for pancreatic cancer patients
por: Zhang, Biao, et al.
Publicado: (2023)

Profiling of immune features to predict immunotherapy efficacy
por: Ye, Youqiong, et al.
Publicado: (2021)

Intratumoral TNFα improves immunotherapy
por: Johansson, Anna, et al.
Publicado: (2012)

The genetic and pharmacogenomic landscape of snoRNAs in human cancer
por: Liu, Yaoming, et al.
Publicado: (2020)

Oncolytic Zika virus promotes intratumoral T cell infiltration and improves immunotherapy efficacy in glioblastoma
por: Chen, Lishu, et al.
Publicado: (2022)

Intratumoral PPT1-positive macrophages determine immunosuppressive contexture and immunotherapy response in hepatocellular carcinoma
por: Weng, Jialei, et al.
Publicado: (2023)

Intratumoral Microbiome of Human Primary Liver Cancer
por: Qu, Dingding, et al.
Publicado: (2022)

The Role of Intratumor Microbiomes in Cervical Cancer Metastasis
por: Jiang, Lu, et al.
Publicado: (2023)

Repurposing infectious disease vaccines for intratumoral immunotherapy
por: Melero, Ignacio, et al.
Publicado: (2020)

Repurposing the yellow fever vaccine for intratumoral immunotherapy
por: Aznar, Maria Angela, et al.
Publicado: (2019)

The Contemporary Landscape and Future Directions of Intratumoral Immunotherapy
por: Brito-Orama, Sebastian, et al.
Publicado: (2023)

Intratumor heterogeneity: the hidden barrier to immunotherapy against MSI tumors from the perspective of IFN-γ signaling and tumor-infiltrating lymphocytes
por: Wu, Wantao, et al.
Publicado: (2021)

Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade?
por: Tang, Fei, et al.
Publicado: (2018)

Simple and effective bacterial-based intratumoral cancer immunotherapy
por: Carroll, Christina S E, et al.
Publicado: (2021)

Intratumoral cancer immunotherapy exploiting anti-viral immunity
por: Kadowaki, Norimitsu
Publicado: (2021)

PancanQTL: systematic identification of cis-eQTLs and trans-eQTLs in 33 cancer types
por: Gong, Jing, et al.
Publicado: (2018)

Radioimmunotherapy‐induced intratumoral changes in cervical squamous cell carcinoma at single‐cell resolution
por: Liu, Chao, et al.
Publicado: (2022)

Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy
por: Jing, Ying, et al.
Publicado: (2020)

Systematic characterization of the tumor microenvironment in Chinese patients with hepatocellular carcinoma highlights intratumoral B cells as a potential immunotherapy target
por: Feng, Yu, et al.
Publicado: (2022)

Clinical response to subcutaneous immunotherapy at 3 years in allergic rhinitis patients is predicted by short‐term treatment effectiveness
por: Liu, Dong, et al.
Publicado: (2023)

Alterations in the human oral microbiome in cholangiocarcinoma
por: Rao, Ben-Chen, et al.
Publicado: (2022)

Intratumoral bacteria interact with metabolites and genetic alterations in hepatocellular carcinoma
por: Xue, Chen, et al.
Publicado: (2022)

Immunotherapy of primary methylcholanthrene-induced mouse tumours by intratumoral BCG.
por: Creau-Goldberg, N., et al.
Publicado: (1980)

Addressing the Adult Soft Tissue Sarcoma Microenvironment with Intratumoral Immunotherapy
por: Raj, Shailaja, et al.
Publicado: (2018)

Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST
por: Goldmacher, Gregory V., et al.
Publicado: (2020)

Maximizing response to intratumoral immunotherapy in mice by tuning local retention
por: Momin, Noor, et al.
Publicado: (2022)

Epitope Characterization of an Aromatase Monoclonal Antibody Suitable for the Assessment of Intratumoral Aromatase Activity
por: Hong, Yanyan, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_7mrmvk706fvb60cjr09vfv87cv